The Motley Fool··David Jagielski, CpaCRISPR Therapeutics Stock Slumps 9% Despite Casgevy Approval and Strong Cash Position
CRISPR Therapeutics stock declined 9% following a $585.2M convertible notes offering. The gene-editing company boasts FDA-approved Casgevy therapy and $1.8B in reserves but faces steep losses.
VRTXCRSPgene editingCasgevy